Skip to main content
NCBI home page
Springer logoLink to Springer
. 2023 Jun 21;33(8):2293–2302. doi: 10.1007/s11695-023-06674-4

The Impact of Bariatric Surgery on the Incidence of Colorectal Cancer in Patients with Obesity—a Systematic Review and Meta-analysis of Registry Data

Matthew G Davey 1,✉, Odhrán K Ryan 2, Éanna J Ryan 3, Noel E Donlon 3, Ian S Reynolds 3, Naomi M Fearon 2, Sean T Martin 2, Helen M Heneghan 2
PMCID: PMC10345076  PMID: 37341934

Abstract

Purpose

Cancer and obesity represent two of the most significant global health concerns. The risk of malignancy, including colorectal cancer (CRC), increases with obesity. The aim of this study was to perform a systematic review and meta-analysis to determine the value of bariatric surgery in reducing CRC risk in patients with obesity using registry data.

Materials and Methods

A systematic review and meta-analysis were performed as per PRISMA guidelines. The risk of CRC was expressed as a dichotomous variable and reported as odds ratios (OR) with 95% confidence intervals (CIs) using the Mantel-Haenszel method. A multi-treatment comparison was performed, examining the risk reduction associated with existing bariatric surgery techniques. Analysis was performed using RevMan, R packages, and Shiny.

Results

Data from 11 registries including 6,214,682 patients with obesity were analyzed. Of these, 14.0% underwent bariatric surgery (872,499/6,214,682), and 86.0% did not undergo surgery (5,432,183/6,214,682). The mean age was 49.8 years, and mean follow-up was 5.1 years. In total, 0.6% of patients who underwent bariatric surgery developed CRC (4,843/872,499), as did 1.0% of unoperated patients with obesity (54,721/5,432,183). Patients with obesity who underwent bariatric surgery were less likely to develop CRC (OR: 0.53, 95% CI: 0.36–0.77, P < 0.001, I2 = 99%). Patients with obesity undergoing gastric bypass surgery (GB) (OR: 0.513, 95% CI: 0.336–0.818) and sleeve gastrectomy (SG) (OR: 0.484, 95% CI: 0.307–0.763) were less likely to develop CRC than unoperated patients.

Conclusion

At a population level, bariatric surgery is associated with reduced CRC risk in patients with obesity. GB and SG are associated with the most significant reduction in CRC risk.

PROSPERO Registration

CRD42022313280.

Graphical Abstract

graphic file with name 11695_2023_6674_Figa_HTML.jpg

Keywords: Bariatric surgery, Colorectal cancer, Meta-analysis, Obesity

Introduction

The incidence of obesity and cancer has been increasing in recent years, contributing to significant challenges to healthcare economies [1, 2]. The incidence of obesity has nearly doubled since 1980 [3], and the prevalence of obesity has recently reached “epidemic proportions” with estimations that 70% of the adult population are now overweight or have obesity [3–5]. Concurrently, the global cancer prevalence continues to increase [2]; therefore, the prioritization of cancer and obesity diagnosis and treatment is of the utmost importance to medicine and surgery in the twenty-first century [6].

Obesity-related cancers account for 11.9% and 13.1% of all cancer diagnoses made in male and female patients respectively [7]. The estimated obesity-related risk of colorectal cancer (CRC) has a dose-response relationship, increasing by 24% in male patients and 9% in female patients with every 5 kg/m2 increase in body mass index (BMI) [8]. Moreover, all measures of adiposity have been shown to increase the risk of CRC in people with obesity [8-12]. Notwithstanding, recent data from the older Swedish Obese Subjects (SOS) study illustrated similar CRC risk in patients with obesity at 22 years of follow-up, irrespective of whether they had undergone bariatric surgery, despite the inclusion of outdated bariatric procedures [13]. Therefore, clarifying the impact of severe obesity on cancer incidence remains a clinical priority to develop mitigation strategies and improve access to obesity treatments [14, 15].

Bariatric surgery has excellent outcomes for treating obesity and obesity-related complications [16], with several studies illustrating improvements in metabolic and cardiovascular diseases and long-term survival [11, 17, 18]. It may also be a promising strategy to reduce cancer incidence in people with obesity [19-21]. Recent recommendations from the American Society for Metabolic and Bariatric Surgery (ASMBS) Clinical Issues Committee highlight the value of bariatric surgery in mitigating obesity-related cancer risk [22], with CRC risk reduced in patients with obesity following bariatric surgery, as illustrated in several previous analyses [23, 24]. Regrettably, these studies failed to provide robust data that could be translatable to a population level. Therefore, the necessity to establish the “real-world” population risk of CRC in patients with obesity who have undergone bariatric surgery compared to their counterparts using large volume, registry data is imperative to ensure accurate and informative preoperative patient counseling.

Accordingly, the aim of the current study was to perform a systematic review and meta-analysis to determine the value of performing bariatric surgery in reducing CRC risk in patients with obesity using registry data only for application to “real-world” decision-making.

Methods

Materials and Methods

A systematic review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist and meta-analysis and systematic reviews of observational studies (MOOSE) guidelines [25, 26]. Local institutional ethical approval was not required for this study. This study was registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42022313280).

Search Strategy

An electronic search was performed of the PUBMED, EMBASE, and Scopus databases on the 18th of February 2022 for relevant studies which would be suitable for inclusion in this study. The search was performed of all fields under the following headings: (bariatric surgeries [MeSH Terms]), (cancer, colorectal [MeSH Terms]), which were linked with the Boolean operator “AND.” Included studies were limited to those published in the English language. Included studies were not restricted based on the year of publication. All titles were initially screened, and studies deemed appropriate had their abstracts and full texts reviewed.

Inclusion and Exclusion Criteria

Studies meeting the following inclusion criteria were included: (1) Studies assessing the value of bariatric surgery to reduce CRC incidence in patients with obesity; (2) eligible studies had to use registry data in their analysis; and (3) studies had to include patients with obesity only. Studies meeting any of the following exclusion criteria were excluded from this study: (1) Studies not evaluating the impact of bariatric surgery on CRC risk; (2) studies including patients without obesity; or (3) studies not using registry data. Where overlapping registries were identified or suspected, the study representing the largest number of patients was included for analysis.

Data Extraction and Quality Assessment

The literature search was performed by two independent reviewers using a predesigned search strategy. Duplicate studies were manually removed. Each reviewer then reviewed the titles, abstracts, and/or full texts of the retrieved manuscripts to ensure all inclusion criteria were met before extracting the following data: (1) first author name, (2) year of publication, (3) study design, (4) country of origin, (5) registry database used, (6) years from which patients were included, (7) number of patients with obesity included, (8) number of patients with obesity included who underwent bariatric surgery, (9) number of patients with obesity included who did not undergo bariatric surgery, (10) number of patients with obesity who underwent bariatric surgery who subsequently developed CRC, and (11) number of patients with obesity included who did not undergo bariatric surgery who subsequently developed CRC. Data specific to patient outcomes and CRC incidence (expressed as hazards ratios (HR), 95% confidence intervals (95% CI), and P values) were directly extracted from tables and study text. HR and associated standard errors were calculated from Kaplan-Meier curves where relevant. In case of discrepancies in opinion between the reviewers, a third reviewer was asked to arbitrate.

Statistical Analysis

Clinicopathological characteristics and outcomes were recorded using descriptive statistics. The Fisher’s exact (†) and chi-square (χ2) tests were used as appropriate to determine the association between bariatric surgery among patients with obesity who subsequently developed CRC [27]. Thereafter, treatment and survival outcomes were expressed as dichotomous or binary outcomes, reported as odds ratios (ORs) and 95% confidence intervals (95% CIs) following estimation using the Mantel-Haenszel method. A meta-analysis of time-to-effect measures from each eligible study was also performed. Estimates of log hazard ratios (HRs) and their standard errors were combined using the generic inverse-variance method. Either fixed- or random-effects models were applied based on whether significant heterogeneity (I2 > 50%) existed between studies included in the analysis. Symmetry of funnel plots was used to assess publication bias. Statistical heterogeneity was determined using I2 statistics. Statistical significance was determined to be P < 0.050. Statistical analysis was performed using Review Manager (RevMan), Version 5.4 (Nordic Cochrane Centre, Copenhagen, Denmark).

Bayesian network meta-analyses (NMAs) were conducted using Netameta and Shiny packages for R to perform a multi-treatment comparison (MTC) of the effect of the available techniques in bariatric surgery [28]. Effect sizes were described with 95% credible intervals (CrIs). Rank probabilities were plotted against the possible ranks for all competing treatments. The confidence in estimates of the outcome was assessed using the “Confidence in Network Meta-Analysis” (CINeMA) [29]. Methodological and risk of bias assessment of the included studies was undertaken using the Newcastle Ottawa Risk of Bias Assessment tool for observational studies [30].

Results

Literature search

The systematic search strategy identified 299 studies, of which 34 duplicate studies were manually removed. The remaining 265 studies had their titles screened for relevance before 49 abstracts, and 27 full texts were reviewed for edibility. Eleven registry studies fulfilled the inclusion criteria and were included in this systematic review [31-41] (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

PRISMA flowchart illustrating the systemic search strategy

Study Characteristics

Of the eleven included studies, six provided registry data in relation to CRC risk following bariatric surgery in the USA (6/11). All included studies were of retrospective design (100.0%, 11/11). Publication dates of included studies ranged from 2009 to 2022, representing patients from 1980 to 2018. Seven studies provided definitions of obesity, with three different definitions used in various registries. The breakdown of the type of bariatric surgery, either laparoscopic gastric bypass surgery (GB), laparoscopic adjustable gastric banding (LAGB), or laparoscopic sleeve gastrectomy (SG), was outlined in ten of the included studies. Data from the included 11 studies are summarized in Table 1.

Table 1.

Details of the 11 included studies in this analysis

Author Year Study Country Registry Years Definition Obesity/Indications for Bariatric Surgery Surgery Details ROB
Adams 2009 RC USA Utah Cancer Registry 1984–2007 BMI >35kg/m2 GBS Low
Aravani 2018 RC UK HES Database 1997–2013 - Multiple Low
Bailly 2020 RC France FNIIS 2009–2018 - LAGB, SG, GBS Low
Ciccioriccio 2021 RC Italy ISOS Database 2010–2015 - SG, GBS Low
Gomez 2020 RC USA NIS 2010–2014 BMI >35 kg/m2 Multiple Low
Khalid 2022 RC USA All Payers Claims Database, Mariner-15 2010–2018 BMI >40 kg/m2 or BMI >35 kg/m2 and at least one obesity related comorbidity SG, GBS Low
Lazzati 2022 RC France National Discharge Database 2010–2017 BMI >40 kg/m2 or BMI >35 kg/m2 and at least one obesity related comorbidity - Low
Rustgi 2021 RC USA WHMSCCE Database 2007–2017 BMI >40 kg/m2 or BMI >35 kg/m2 and at least one obesity related comorbidity Multiple Some
Schauer 2019 RC USA Kaiser Permanente 2004–2014 BMI >35 kg/m2 Multiple Low
Tao 2019 RC Scandinavia NOS Database 1980–2015 - Multiple Low
Tsui 2020 RC USA NYSPRCS Database 2006–2012 BMI >30 kg/m2 LAGB, SG, GBS Some
Open in a new tab

RC retrospective cohort, USA United States of America, UK United Kingdom, BMI body mass index, GBS gastric bypass surgery, SG sleeve gastrectomy, LAGB laparoscopic gastric band, HES hospital episode statistics, FNIIS French National Insurance Information System, ISOS Italian Society of Obesity Surgery, NIS national inpatient sample, WHMSCCE Watson Health Market Scan Commercial Claims and Encounters, NOS Nordic Obesity Surgery, NYSPRCS New York State–wise Planning and Research Cooperative System, ROB risk of bias assessment performed in accordance with Newcastle Ottawa Scale

Clinicopathological Characteristics

From the 11 independent registries, 6,214,682 patients with obesity were included. Of these, 14.0% underwent bariatric surgery (872,499/6,214,682) and 86.0% did not undergo bariatric surgery (5,432,183/6,214,682). Nine studies reported follow-up data, and the mean follow-up was 5.1 years (range: 0–20 years). Five studies reported patient age, and the mean age of included patients was 49.8 years (Table 2).

Table 2.

Colorectal cancer data for included obese patients

Author Number Follow-up in years (range) Mean age (Years) Number Surgery Number No Surgery CRC Surgery CRC No Surgery
Adams 16,037 12.5 - 6595 9442 25 52
Aravani 1,002,607 3.0 (1–16) - 39,747 962,860 43 3237
Bailly 1,045,348 5.3 57.3 74,131 971,217 423 12,629
Ciccioriccio 20,571 4.3 (5–10) 43.6 20,571 - 22 -
Gomez 1,837,594 3.5 53.9 247,015 1,590,579 3540 29,822
Khalid 28,908 5.0 - 19,272 9636 66 55
Lazzati 1,140,347 5.7 49 288,604 851,743 329 4434
Rustgi 98,090 - - 33,435 64.655 - -
Schauer 88,625 3.5 45.1 22.198 66.427 - -
Tao 542,358 4.2 (0–20) - 49,931 492,427 155 3158
Tsui 394,197 - - 71,000 323,197 240 1334
6,214,682 5.1 years 49.8 872,499 5,342,183 4843 54,721
Open in a new tab

CRC colorectal cancer

Colorectal Cancer Risk following Bariatric Surgery

Overall, patients with obesity who underwent bariatric surgery were less likely to develop CRC than their counterparts (P < 0.001, †). In total, 0.6% of patients with obesity who underwent bariatric surgery later developed CRC (4843/872,499), while 1.0% of patients with obesity who did not undergo bariatric surgery later developed CRC (54,721/5,432,183) (Table 3). Eight studies provided data for inclusion in the meta-analysis [31–33, 35–37, 40, 41]. Patients living with obesity who underwent bariatric surgery were less likely to develop CRC than their counterparts (OR: 0.53, 95% CI: 0.36–0.77, P < 0.001, I2 = 99%) (Fig. 2). Eight studies used time to effect modeling to establish CRC risk following bariatric surgery [31-33, 35–38, 40]. In this analysis, patients with obesity who did not undergo bariatric surgery were more likely to develop CRC than their counterparts who underwent bariatric surgery (OR: 1.12, 95% CI: 1.02–1.23, P < 0.001, I2 = 94%) (Fig. 3).

Table 3.

Risk of developing colorectal cancer in those who underwent bariatric surgery and in unoperated patients

Bariatric surgery No surgery P value
Colorectal cancer 4,843 (0.6%) 54,721 (1.0%) <0.001*, †
No colorectal cancer 867,656 (99.4%) 5,377,462 (99.0%)
Open in a new tab

*Denotes statistical significance

†Denotes Fisher’s exact test

Fig. 2.

Fig. 2

Open in a new tab

Forest plot illustrating colorectal cancer risk in obese patients who underwent bariatric surgery and those who did not

Fig. 3.

Fig. 3

Open in a new tab

Forest plot illustrating the risk of colorectal cancer in obese patients who underwent bariatric surgery and those who did not using generic inverse variance time-to-effect analysis

Colorectal Cancer Risk by Bariatric Surgery

Four studies provided data for inclusion in NMA [33, 34, 36, 41]. These included data in relation to 1,476,151 patients with obesity, of whom 88.3% did not undergo surgery, 2.5% underwent LAGB (35,247/1,476,151), 4.6% underwent SG (67,387/1,476,151), and 4.6% underwent GB (68,477/1,476,151).

Of those who did not undergo surgery, 1.1% developed CRC (14,018/1,304,050). Of those who underwent LAGB, 0.5% developed CRC (185/36,237). Of those who underwent SG, 0.4% developed CRC (253/67,387). Of those who underwent GB, 0.3% developed CRC (236/68,477) (P < 0.001, χ2) (Table 4). At NMA, patients with obesity undergoing GB (OR: 0.513, 95% CI: 0.336–0.818) and SG (OR: 0.484, 95% CI: 0.307–0.763) were less likely to develop CRC than those who did not undergo bariatric surgery (Fig. 4). Overall study results and the associated network plot are outlined in Figs. 5 and 6. The ranking table for these analyses is illustrated in Table 5.

Table 4.

Risk of developing colorectal cancer based on bariatric surgery type and in unoperated patients

No Surgery LAGB SG GBS P value
Colorectal Cancer 14,018 (1.1%) 185 (0.5%) 253 (0.4%) 236 (0.3%) <0.001*, χ2
No Colorectal Cancer 1,290,032 (98.9%) 36,052 (99.5%) 67,134 (99.6%) 68,241 (99.7%)
Open in a new tab

LAGB laparoscopic gastric band, SG sleeve gastrectomy, GBS gastric bypass surgery

*Denotes statistical significance

χ2Denotes chi-square test

Fig. 4.

Fig. 4

Open in a new tab

Forest plot comparing the risk of colorectal cancer in obese patients who underwent gastric banding, gastric bypass, sleeve gastrectomy, and no previous bariatric surgery

Fig. 5.

Fig. 5

Open in a new tab

Data summary for all individual studies included in the network meta-analysis assessing colorectal cancer for each surgical approach (represented as odds ratios and 95% confidence intervals)

Fig. 6.

Fig. 6

Open in a new tab

Network plot for all individual studies included in the network meta-analysis

Table 5.

Ranking table for the bariatric surgery approaches and their impact on colorectal cancer risk

- Rank 1 Rank 2 Rank 3 Rank 4
Sleeve gastrectomy 0.5987625 0.34635 0.0531 0.0017875
Bypass surgery 0.358525 0.5490125 0.0885375 0.003925
Laparoscopic gastric banding 0.0418875 0.100325 0.796525 0.0612625
No surgery 0.000825 0.0043125 0.0618375 0.933025
Open in a new tab

Risk of Bias Assessment

There was low-to-moderate risk of bias among the included studies: Overall, 9 of the included studies had low risk of bias (81.8%) [31-36, 39, 40], while just 2 of the studies included illustrated some concerns for bias (18.2%) [38, 41]. None of the included studies were concerned to have a high risk of bias. Risk of bias assessment using the Newcastle Ottawa Scale is demonstrated in Table 1.

Discussion

An almost 50% relative reduction in CRC was observed in those who underwent bariatric surgery at a mean follow-up of 5 years. This analysis included data from 11 independent registries, which encompassed 6.2 million patients with obesity. The most important finding in this study was the data supporting the role of bariatric surgery in reducing the risk of developing CRC in patients with obesity, supporting the work of previous authors [23, 24, 42]. The results illustrate the potentially beneficial implications of bariatric surgery at a population level in reducing CRC development. At present, there is a lack of awareness regarding the relationship between obesity and the risk of developing cancers. Most patients are unaware that obesity affects their cancer risk [43–45], despite being aware of an increased risk of cardiovascular and diabetic complications [46]. When informed of this causative link, most patients are willing to attempt weight loss interventions, including bariatric surgery [43, 45]. Thus, discussing the potentially protective role of bariatric surgery in reducing future CRC risk, among other obesity-related malignancies and diseases, could be incorporated into preoperative counseling for patients suitable to undergo bariatric surgery [47–51].

In this study, people with obesity who underwent bariatric surgery had a reduced incidence of CRC relative to their counterparts who did not undergo surgery. Overall, the absolute risk of developing subsequent CRC was reduced to 0.4% (0.6%, 4,843/872,499 vs. 1.0%, 54,721/5,432,183), as well as an estimated relative reduction of 47% observed in this analysis of over 6.2 million people with obesity (OR: 0.53, 95% CI: 0.36–0.77). These findings support the data provided by previous meta-analyses: In their analysis of over 1.2 million patients, Almazedi et al. illustrated a 35% reduction in CRC risk for people with obesity who underwent bariatric surgery [24]. Afshar et al. previously described a reduced risk of CRC following bariatric surgery in their meta-analysis, which included over 100,000 patients with obesity (OR: 0.73, 95% CI: 0.59–0.90) [23]. While patients with obesity have a greater propensity to develop cancers such as CRC [52–54], the multidisciplinary team is further challenged in providing equitable treatment and care for these patients due to the added complexity of healthcare provision for patients with obesity [55]. Therefore, managing patients with obesity present an imminent challenge for healthcare services in ensuring patient outcomes are optimized for this unique and increasingly prevalent patient subgroup [3–5].

Interestingly, patients with obesity who underwent laparoscopic sleeve gastrectomy (OR: 0.484, 95% CI: 0.307–0.763) or laparoscopic gastric bypass (OR: 0.513, 95% CI: 0.336–0.818) were significantly less likely to develop CRC than those who did not undergo bariatric surgery. A laparoscopic gastric bypass is a more technically challenging procedure associated with slightly increased morbidity and mortality rates; however, long-term outcomes are similar. [56]. While implications of such bariatric surgeries on oncological outcomes (such as CRC risk) are important, the primary rationale is to improve patient health and quality of life. Several contemporary, robust analyses of high-quality evidence have evaluated the implications of bariatric procedures on human health: Kang et al. reported on a NMA of randomized controlled trials (RCTs) where the mean BMI reduction observed for SG were 14.4 kg/m2 (n = 257), 13.5 kg/m2 for GB (n = 355), and 10.6 kg/m2 for LAGB (n = 153) [57]. Ding et al. performed an NMA of RCTs which illustrated the value of both GB and SG for maintaining long-term remission of type 2 diabetes mellitus relative to LAGB [58]. Interestingly, some studies have linked bariatric surgery to an increased risk of CRC: In their analysis of 77,111 patients with obesity, Derogar et al. observed an increase in CRC incidence in patients with obesity who underwent bariatric surgery over time (OR: 1.60, 95% CI: 1.25–2.02), which doubled 10 years following surgery (OR: 2.00, 95% CI: 1.48–2.64) [59]. Similarly, Ostlund et al. analyzed the Swedish cancer registry data to establish an increased risk of CRC following bariatric surgery (OR: 1.52, 95% CI: .06–2.11) [60]. These results are refuted by the data of the current analysis. Thus, while SG and GB improve CRC risk relative to LAGB and no surgery, pre-operative counseling and decision-making should include the important medical and oncological data reported by these previous authors in conjunction with the current analysis results.

While data from Memorial Sloan Kettering and MD Anderson Cancer Centre illustrate no compromise in short-term surgical outcomes following CRC resection [61, 62], the data illustrating the contributary role of obesity to CRC development is irrefutable [10-12]. Obesity is associated with a state of chronic inflammation and immune paralysis [63], which is correlated directly with an increased risk of malignancy [64, 65]. There is excessive availability of macronutrients in adipocytes which stimulates an endogenous release of inflammatory markers (such as tumor necrosis factor-alpha (TNF-a) and interleukin-6 (Il-6)) while reducing adiponectin production, ultimately inducing a pro-inflammatory state of excessive oxidative stress [64, 66]. Excessive inflammation within cancer cells and the associated local stromal and inflammatory cells promote oncogenesis, leading to a pro-inflammatory tumor microenvironment [65, 67], which promotes oncogenesis at all stages. Furthermore, increased insulin and insulin-like growth factor-1 (IGF-1) concentrations in the circulation of humans have been illustrated to independently predict malignancy incidence [68]. This reported correlation and cancer incidence are likely due to the direct effect of such hormones on the receptors of the external cellular surface of specific cancer cells, which then act as downstream mediators in the canonical insulin signaling cascade within these cells [69], promoting tumor development. Notwithstanding the long-term durability of bariatric surgery in facilitating weight loss and metabolic improvement [70], it is plausible that there may be secondary implications for reducing CRC risk.

The current study has several limitations. Firstly, the data used in this analysis was obtained from regional, national, and international registries, rendering the data subject to the inherent limitations associated with relying on registry data [71], and relying on a moderate level of evidence to provide informative results into a complex healthcare concern. Secondly, patients included in this study span four decades. During this period, we have observed the evolution in bariatric surgical practice and a significant increase in trends in the obesity and CRC incidence, as well as the indications for bariatric surgery [16, 72, 73]. Finally, the current analysis falls short of addressing the impact of bariatric surgery on reducing CRC within subgroup populations, including those based on age, gender, and ethnicity, while lacking long-term follow-up data, including cancer survival and recurrence. Nevertheless, the authors wish to highlight that the current meta-analysis of over 6.2 million patients further establishes the clinical role of bariatric surgery in reducing CRC risk in patients with obesity at a population level.

In conclusion, the current systematic review and meta-analysis illustrate the potential role of bariatric surgery in reducing future CRC in patients with obesity at a population level. GB and SG provide the greatest reduction in CRC risk. Patient counseling and shared decision-making ab initio of their bariatric surgery should include this data on CRC incidence in conjunction with the other important health implications of bariatric surgery.

Funding

Open Access funding provided by the IReL Consortium

Declarations

Ethical Approval

This study is a review of current evidence and therefore did not require study specific ethical approval.

Informed Written Consent

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Studies with Human Participants

Not applicable.

Footnotes

Key Points

• Bariatric surgery reduced colorectal cancer (CRC) incidence in patients with obesity.

• Gastric bypass and sleeve gastrectomy induced the most significant reduction in CRC.

• A 50% relative reduction in CRC was observed overall.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Hulvat MC. Cancer incidence and trends. Surg Clin North Am. 2020;100(3):469–481. doi: 10.1016/j.suc.2020.01.002. [DOI] [PubMed] [Google Scholar]
  • 2.Allemani C, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Finucane MM, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–567. doi: 10.1016/S0140-6736(10)62037-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ng M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781. doi: 10.1016/S0140-6736(14)60460-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sanchis-Gomar F, et al. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc. 2020;95(7):1445–1453. doi: 10.1016/j.mayocp.2020.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kaidar-Person O, Bar-Sela G, Person B. The two major epidemics of the twenty-first century: obesity and cancer. Obes Surg. 2011;21(11):1792–1797. doi: 10.1007/s11695-011-0490-2. [DOI] [PubMed] [Google Scholar]
  • 7.Avgerinos KI, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–135. doi: 10.1016/j.metabol.2018.11.001. [DOI] [PubMed] [Google Scholar]
  • 8.Renehan AG, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. doi: 10.1016/S0140-6736(08)60269-X. [DOI] [PubMed] [Google Scholar]
  • 9.Ma Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PloS One. 2013;8(1):e53916. doi: 10.1371/journal.pone.0053916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sjöström L, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653–662. doi: 10.1016/S1470-2045(09)70159-7. [DOI] [PubMed] [Google Scholar]
  • 11.Sjöström L, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–752. doi: 10.1056/NEJMoa066254. [DOI] [PubMed] [Google Scholar]
  • 12.Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–498. doi: 10.1038/nrc3967. [DOI] [PubMed] [Google Scholar]
  • 13.Taube M, et al. Long-term incidence of colorectal cancer after bariatric surgery or usual care in the Swedish Obese Subjects study. PloS One. 2021;16(3):e0248550. doi: 10.1371/journal.pone.0248550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dyer KE, et al. The contribution of body mass index to appraisal delay in colorectal cancer diagnosis: a structural equation modelling study. Br J Cancer. 2017;116(12):1638–1642. doi: 10.1038/bjc.2017.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Vernaci G, et al. BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. Breast. 2019;47:77–84. doi: 10.1016/j.breast.2019.07.003. [DOI] [PubMed] [Google Scholar]
  • 16.Alalwan AA, et al. US national trends in bariatric surgery: A decade of study. Surgery. 2021;170(1):13–17. doi: 10.1016/j.surg.2021.02.002. [DOI] [PubMed] [Google Scholar]
  • 17.Doumouras AG, et al. Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:: A Population-Based Retrospective Cohort Study. Circulation. 2021;143(15):1468–1480. doi: 10.1161/CIRCULATIONAHA.120.052386. [DOI] [PubMed] [Google Scholar]
  • 18.Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Metabolic and Endocrine Consequences of Bariatric Surgery. Front Endocrinol (Lausanne) 2019;10:626. doi: 10.3389/fendo.2019.00626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mackenzie H, et al. Obesity surgery and risk of cancer. Br J Surg. 2018;105(12):1650–1657. doi: 10.1002/bjs.10914. [DOI] [PubMed] [Google Scholar]
  • 20.Hassinger TE, et al. Overall and Estrogen Receptor-Positive Breast Cancer Incidences Are Decreased Following Bariatric Surgery. Obes Surg. 2019;29(3):776–781. doi: 10.1007/s11695-018-3598-9. [DOI] [PubMed] [Google Scholar]
  • 21.Feigelson HS, et al. Bariatric Surgery is Associated With Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women. Ann Surg. 2020;272(6):1053–1059. doi: 10.1097/SLA.0000000000003331. [DOI] [PubMed] [Google Scholar]
  • 22.Ghiassi S, et al. ASMBS position statement on the relationship between obesity and cancer, and the role of bariatric surgery: risk, timing of treatment, effects on disease biology, and qualification for surgery. Surg Obes Relat Dis. 2020;16(6):713–724. doi: 10.1016/j.soard.2020.03.019. [DOI] [PubMed] [Google Scholar]
  • 23.Afshar S, et al. Biomarkers of Colorectal Cancer Risk Decrease 6 months After Roux-en-Y Gastric Bypass Surgery. Obes Surg. 2018;28(4):945–954. doi: 10.1007/s11695-017-2953-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Almazeedi S, et al. Role of bariatric surgery in reducing the risk of colorectal cancer: a meta-analysis. Br J Surg. 2020;107(4):348–354. doi: 10.1002/bjs.11494. [DOI] [PubMed] [Google Scholar]
  • 25.Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–2012. doi: 10.1001/jama.283.15.2008. [DOI] [PubMed] [Google Scholar]
  • 27.Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. Restor Dent Endod. 2017;42(2):152–155. doi: 10.5395/rde.2017.42.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Owen RK, et al. MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10(4):569–581. doi: 10.1002/jrsm.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z. [DOI] [PubMed] [Google Scholar]
  • 31.Adams TD, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009;17(4):796–802. doi: 10.1038/oby.2008.610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Aravani A, et al. Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. Cancer Epidemiol. 2018;53:99–104. doi: 10.1016/j.canep.2018.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bailly L, et al. Colorectal Cancer Risk Following Bariatric Surgery in a Nationwide Study of French Individuals With Obesity. JAMA Surg. 2020;155(5):395–402. doi: 10.1001/jamasurg.2020.0089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ciccioriccio MC, et al. Colorectal cancer after bariatric surgery (Cric-Abs 2020): Sicob (Italian society of obesity surgery) endorsed national survey. Int J Obes (Lond) 2021;45(12):2527–2531. doi: 10.1038/s41366-021-00910-6. [DOI] [PubMed] [Google Scholar]
  • 35.Gómez CO, et al. Bariatric surgery decreases the number of first-time hospital admissions for cancer in severely obese patients. A retrospective analysis of the National Inpatient Sample database. Surg Obes Relat Dis. 2020;16(11):1648–1654. doi: 10.1016/j.soard.2020.07.017. [DOI] [PubMed] [Google Scholar]
  • 36.Khalid SI, et al. Association of Bariatric Surgery and Risk of Cancer in Patients With Morbid Obesity. Ann Surg. 2022;275(1):1–6. doi: 10.1097/SLA.0000000000005035. [DOI] [PubMed] [Google Scholar]
  • 37.Lazzati A, et al. Effect of bariatric surgery on cancer risk: results from an emulated target trial using population-based data. Br J Surg. 2022;109(5):433–8. [DOI] [PubMed]
  • 38.Rustgi VK, et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology. 2021;161(1):171–184.e10. doi: 10.1053/j.gastro.2021.03.021. [DOI] [PubMed] [Google Scholar]
  • 39.Schauer DP, et al. Bariatric Surgery and the Risk of Cancer in a Large Multisite Cohort. Ann Surg. 2019;269(1):95–101. doi: 10.1097/SLA.0000000000002525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tao W, et al. Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. Int J Cancer. 2020;147(3):728–735. doi: 10.1002/ijc.32770. [DOI] [PubMed] [Google Scholar]
  • 41.Tsui ST, et al. Development of cancer after bariatric surgery. Surg Obes Relat Dis. 2020;16(10):1586–1595. doi: 10.1016/j.soard.2020.06.026. [DOI] [PubMed] [Google Scholar]
  • 42.Janik MR, et al. The effect of bariatric surgery on reducing the risk of colorectal cancer: a meta-analysis of 3,233,044 patients. Surg Obes Relat Dis. 2023;19(4):328–334. doi: 10.1016/j.soard.2022.10.003. [DOI] [PubMed] [Google Scholar]
  • 43.Soliman PT, et al. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol. 2008;112(4):835–842. doi: 10.1097/AOG.0b013e318187d022. [DOI] [PubMed] [Google Scholar]
  • 44.Beavis AL, et al. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep. 2015;13:71–75. doi: 10.1016/j.gore.2015.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wilkinson M, et al. Patient perceptions and understanding of obesity related endometrial cancer. Gynecol Oncol Rep. 2020;32:100545. doi: 10.1016/j.gore.2020.100545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Clark LH, et al. Endometrial Cancer Survivors' Perceptions of Provider Obesity Counseling and Attempted Behavior Change: Are We Seizing the Moment? Int J Gynecol Cancer. 2016;26(2):318–324. doi: 10.1097/IGC.0000000000000596. [DOI] [PubMed] [Google Scholar]
  • 47.Wiggins T, Antonowicz SS, Markar SR. Cancer Risk Following Bariatric Surgery-Systematic Review and Meta-analysis of National Population-Based Cohort Studies. Obes Surg. 2019;29(3):1031–1039. doi: 10.1007/s11695-018-3501-8. [DOI] [PubMed] [Google Scholar]
  • 48.Tao W, et al. Cancer Risk After Bariatric Surgery in a Cohort Study from the Five Nordic Countries. Obes Surg. 2020;30(10):3761–3767. doi: 10.1007/s11695-020-04751-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Schiavon CA, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension) Circulation. 2018;137(11):1132–1142. doi: 10.1161/CIRCULATIONAHA.117.032130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Winder AA, Kularatna M, MacCormick AD. Does bariatric surgery affect the incidence of breast cancer development? A systematic review. Obes Surg. 2017;27(11):3014–3020. doi: 10.1007/s11695-017-2901-5. [DOI] [PubMed] [Google Scholar]
  • 51.Zhang K, et al. Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis. Obes Surg. 2020;30(4):1265–1272. doi: 10.1007/s11695-019-04368-4. [DOI] [PubMed] [Google Scholar]
  • 52.Engin A. Obesity-associated Breast Cancer: Analysis of risk factors. Adv Exp Med Biol. 2017;960:571–606. doi: 10.1007/978-3-319-48382-5_25. [DOI] [PubMed] [Google Scholar]
  • 53.Dong Y, et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017;37(6):BSR20170945. doi: 10.1042/BSR20170945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol. 2016;34(35):4225–4230. doi: 10.1200/JCO.2016.69.4638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Wolfenden L, et al. The challenge for global health systems in preventing and managing obesity. Obes Rev. 2019;20(Suppl 2):185–193. doi: 10.1111/obr.12872. [DOI] [PubMed] [Google Scholar]
  • 56.Carlin AM, et al. The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. Ann Surg. 2013;257(5):791–797. doi: 10.1097/SLA.0b013e3182879ded. [DOI] [PubMed] [Google Scholar]
  • 57.Kang JH, Le QA. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Medicine. 2017;96(46):e8632. [DOI] [PMC free article] [PubMed]
  • 58.Ding L, et al. Comparative effectiveness of bariatric surgeries in patients with obesity and type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. Obes Rev. 2020;21(8):e13030. doi: 10.1111/obr.13030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Derogar M, et al. Increased risk of colorectal cancer after obesity surgery. Ann Surg. 2013;258(6):983–988. doi: 10.1097/SLA.0b013e318288463a. [DOI] [PubMed] [Google Scholar]
  • 60.Ostlund MP, Lu Y, Lagergren J. Risk of obesity-related cancer after obesity surgery in a population-based cohort study. Ann Surg. 2010;252(6):972–6. doi: 10.1097/SLA.0b013e3181e33778. [DOI] [PubMed] [Google Scholar]
  • 61.Chern H, et al. Effects of obesity in rectal cancer surgery. J Am Coll Surg. 2010;211(1):55–60. doi: 10.1016/j.jamcollsurg.2010.03.010. [DOI] [PubMed] [Google Scholar]
  • 62.Peacock O, et al. Robotic rectal cancer surgery: comparative study of the impact of obesity on early outcomes. Br J Surg. 2020;107(12):1552–1557. doi: 10.1002/bjs.12023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zatterale F, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2019;10:1607. doi: 10.3389/fphys.2019.01607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Ellulu MS, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851–863. doi: 10.5114/aoms.2016.58928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41. doi: 10.1016/j.immuni.2019.06.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer. 2021;125(4):495–509. doi: 10.1038/s41416-021-01393-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Zhao H, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi: 10.1038/s41392-021-00658-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058–4065. doi: 10.1200/JCO.2010.27.9935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Rabin-Court A, et al. Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation. PloS One. 2019;14(6):e0218126. doi: 10.1371/journal.pone.0218126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Maciejewski ML, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016;151(11):1046–1055. doi: 10.1001/jamasurg.2016.2317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Williams WG. Uses and limitations of registry and academic databases. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2010;13(1):66–70. doi: 10.1053/j.pcsu.2010.02.007. [DOI] [PubMed] [Google Scholar]
  • 72.Inoue Y, et al. Epidemiology of Obesity in Adults: Latest Trends. Curr Obes Rep. 2018;7(4):276–288. doi: 10.1007/s13679-018-0317-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Siegel RL, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164. doi: 10.3322/caac.21601. [DOI] [PubMed] [Google Scholar]

Articles from Obesity Surgery are provided here courtesy of Springer

RESOURCES